Skip to main content

Table 1 Selected characteristics of the study population

From: Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study

Characteristic Controls (n = 3,065) Ductal cancer (n = 1,888) Lobular cancer (n = 308) Tubular cancer (n = 93)
  No. (%) No. (%) No. (%) No. (%)
Age (years)     
   50–54 233 (8) 195 (10) 31 (10) 9 (10)
   55–59 582 (19) 431 (23) 70 (23) 20 (22)
   60–64 678 (22) 390 (21) 61 (20) 26 (28)
   65–69 790 (26) 473 (25) 73 (24) 23 (25)
   70–74 782 (26) 399 (21) 73 (24) 15 (16)
Surgical menopause     
   Yes 125 (4) 85 (5) 11 (4) 5 (5)
   Unknown 10 27 5 1
Menopausal symptoms     
   Yes 1,469 (57) 1,113 (60) 186 (61) 62 (67)
   Unknown 477 29 2 1
Socioeconomic status     
   Blue collar worker 830 (32) 549 (29) 93 (30) 18 (20)
   White collar worker 1,412 (54) 1,081 (58) 175 (57) 60 (67)
   Other 337 (14) 248 (13) 39 (13) 12 (13)
   Unknown 450 10 1 3
Ever use of menopausal hormone therapy     
   Any type 1,185 (39) 891 (47) 170 (55) 55 (59)
   Unknown 24 5 1 0
   Estrogen (+/- progestin) 612 (20) 533 (28) 116 (38) 40 (43)
Estradiol 506 (17) 452 (24) 100 (33) 36 (39)
Conjugated estrogens 69 (2) 80 (4) 17 (6) 5 (5)
Other estrogens 19 (0.6) 17 (0.9) 3 (1) 1 (1)
   Administration of estrogen     
Tablets 526 (17) 465 (25) 103 (34) 39 (42)
Patches 123 (4) 114 (6) 18 (6) 4 (4)
Injections 20 (0.7) 12 (0.6) 1 (0.3) 1 (1)
   Progestin (+/- estrogen) 462 (15) 420 (22) 95 (31) 38 (41)
Progesterone derived progestin 138 (5) 126 (7) 39 (13) 9 (10)
Testosterone derived progestin 371 (12) 353 (19) 79 (26) 35 (38)
   Low potency oral estrogen 354 (12) 224 (12) 45 (15) 9 (10)
   Local estrogen 374 (12) 260 (14) 33 (11) 12 (13)